Drugs Made In America Acquisition II Corp.

Drugs Made In America Acquisition II Corp. (Nasdaq: DMII) is a blank-check company that completed its initial public offering in September 2025, filing a 424B4 prospectus on September 25 of that year. The vehicle is the second SPAC under the Drugs Made In America franchise, targeting opportunities in the pharmaceutical and domestic drug manufacturing sector. As of its IPO date, DMII is in the target-search phase, seeking a business combination partner in healthcare or related industries. The SPAC's sector focus centers on onshore pharmaceutical production, an area of ongoing regulatory and investor attention. Sign up at SpacDesk for the full filing history, deal timeline, and analytics on DMII.